ASX:SPL - AstraZeneca DEP Bcl2/xL inhibitors show compelling efficacy

Starpharma

Company

About Starpharma Leadership Our Brands Our Capabilities Research Publications ESG

DEP® Platform

Dendrimer Technology DEP® Drug Delivery Platform DEP® Solutions Our DEP® Pipeline

Partnerships

Partnering with Starpharma Star Navigator

Investors

Why Invest ASX Announcements Entitlement Offer News & Updates Investor Presentations Video Library Financial Reports Annual General Meeting 2025 Market Data Stock Listing Shareholder Services Corporate Governance

People & Culture

Our People & Culture Careers

AstraZeneca DEP Bcl2/xL inhibitors show compelling efficacy

Your question will be sent privately to Starpharma. The company may choose to make this question public.

Start the conversation

Ask Starpharma a question about this announcement.

Share your feedback

Discover